Cortical Lewy body injections induce long-distance pathogenic alterations in the non-human primate brain

[1]  J. Attems,et al.  Dopamine and vesicular monoamine transport loss supports incidental Lewy body disease as preclinical idiopathic Parkinson , 2023, NPJ Parkinson's disease.

[2]  E. Bézard,et al.  Functional and neuropathological changes induced by injection of distinct alpha-synuclein strains: A pilot study in non-human primates , 2023, Neurobiology of Disease.

[3]  J. Laurens.  The statistical power of three monkeys , 2022, bioRxiv.

[4]  E. Bézard,et al.  Acidic nanoparticles protect against α‐synuclein‐induced neurodegeneration through the restoration of lysosomal function , 2022, Aging cell.

[5]  E. Bézard,et al.  Brain injections of glial cytoplasmic inclusions induce a multiple system atrophy-like pathology. , 2022, Brain : a journal of neurology.

[6]  E. Bézard.  How Lazy Reading and Semantic Sloppiness May Harm Progress in Synucleinopathy Research , 2022, Biomolecules.

[7]  E. Bézard,et al.  Motor and non-motor circuit disturbances in early Parkinson disease: which happens first? , 2021, Nature Reviews Neuroscience.

[8]  S. Haber,et al.  Prefrontal connectomics: from anatomy to human imaging , 2021, Neuropsychopharmacology.

[9]  J. Raber,et al.  Effects of Alpha-Synuclein Targeted Antisense Oligonucleotides on Lewy Body-Like Pathology and Behavioral Disturbances Induced by Injections of Pre-Formed Fibrils in the Mouse Motor Cortex , 2021, Journal of Parkinson's disease.

[10]  N. Narayanan,et al.  Cortical alpha-synuclein preformed fibrils do not affect interval timing in mice , 2021, Neuroscience Letters.

[11]  Marie-Laure Arotcarena,et al.  A New Rise of Non-Human Primate Models of Synucleinopathies , 2021, Biomedicines.

[12]  H. Lashuel,et al.  Reverse engineering Lewy bodies: how far have we come and how far can we go? , 2021, Nature Reviews Neuroscience.

[13]  Qin Li,et al.  L‐DOPA regulates α‐synuclein accumulation in experimental parkinsonism , 2020, Neuropathology and applied neurobiology.

[14]  D. Dickson,et al.  Trans-synaptic and retrograde axonal spread of Lewy pathology following pre-formed fibril injection in an in vivo A53T alpha-synuclein mouse model of synucleinopathy , 2020, Acta Neuropathologica Communications.

[15]  D. Dickson,et al.  Trans-synaptic and retrograde axonal spread of Lewy pathology following pre-formed fibril injection in an in vivo A53T alpha-synuclein mouse model of synucleinopathy , 2020, Acta neuropathologica communications.

[16]  Federico N. Soria,et al.  Synucleinopathy alters nanoscale organization and diffusion in the brain extracellular space through hyaluronan remodeling , 2020, Nature Communications.

[17]  P. T. Ten Eyck,et al.  Local cortical overexpression of human wild-type alpha-synuclein leads to increased dendritic spine density in mouse , 2020, Neuroscience Letters.

[18]  N. Rougier,et al.  Identification of distinct pathological signatures induced by patient-derived α-synuclein structures in nonhuman primates , 2020, Science Advances.

[19]  E. Bézard,et al.  Bidirectional gut-to-brain and brain-to-gut propagation of synucleinopathy in non-human primates. , 2020, Brain : a journal of neurology.

[20]  R. Moratalla,et al.  Modeling Parkinson’s Disease With the Alpha-Synuclein Protein , 2020, Frontiers in Pharmacology.

[21]  E. Bézard,et al.  Targeting α-Synuclein for PD Therapeutics: A Pursuit on All Fronts , 2020, Biomolecules.

[22]  J. Trojanowski,et al.  Intrastriatal alpha-synuclein fibrils in monkeys: spreading, imaging and neuropathological changes. , 2019, Brain : a journal of neurology.

[23]  W. Oertel,et al.  Neuronal vulnerability in Parkinson disease: Should the focus be on axons and synaptic terminals? , 2019, Movement disorders : official journal of the Movement Disorder Society.

[24]  Seung-Jae Lee,et al.  Modeling α-Synuclein Propagation with Preformed Fibril Injections , 2019, Journal of movement disorders.

[25]  Hyungwon Choi,et al.  Moving beyond P values: data analysis with estimation graphics , 2019, Nature Methods.

[26]  A. Recasens,et al.  In vivo models of alpha-synuclein transmission and propagation , 2018, Cell and Tissue Research.

[27]  John L. Robinson,et al.  Cellular Milieu Imparts Distinct Pathological α-Synuclein Strains in α-Synucleinopathies , 2018, Nature.

[28]  B. Hyman,et al.  Synaptic phosphorylated &agr;-synuclein in dementia with Lewy bodies , 2017, Brain : a journal of neurology.

[29]  Marie Carlén,et al.  What constitutes the prefrontal cortex? , 2017, Science.

[30]  Federico N. Soria,et al.  Glucocerebrosidase deficiency in dopaminergic neurons induces microglial activation without neurodegeneration , 2017, Human molecular genetics.

[31]  J. Brotchie,et al.  Animal models of α-synucleinopathy for Parkinson disease drug development , 2017, Nature Reviews Neuroscience.

[32]  D. James Surmeier,et al.  Selective neuronal vulnerability in Parkinson disease , 2017, Nature Reviews Neuroscience.

[33]  Suzanne N. Haber,et al.  Corticostriatal circuitry , 2016, Dialogues in clinical neuroscience.

[34]  D. Geschwind,et al.  Evidence for α-synuclein prions causing multiple system atrophy in humans with parkinsonism , 2015, Proceedings of the National Academy of Sciences.

[35]  Vivek K Unni,et al.  Progressive aggregation of alpha-synuclein and selective degeneration of Lewy inclusion-bearing neurons in a mouse model of parkinsonism , 2015, Cell reports.

[36]  S. Haber,et al.  Estimates of Projection Overlap and Zones of Convergence within Frontal-Striatal Circuits , 2014, The Journal of Neuroscience.

[37]  S. Chandra,et al.  Synucleins Regulate the Kinetics of Synaptic Vesicle Endocytosis , 2014, The Journal of Neuroscience.

[38]  E. Bézard,et al.  Lewy body extracts from Parkinson disease brains trigger α‐synuclein pathology and neurodegeneration in mice and monkeys , 2014, Annals of neurology.

[39]  Robert E. Burke,et al.  Axon degeneration in Parkinson's disease , 2013, Experimental Neurology.

[40]  Masato Hasegawa,et al.  Prion-like spreading of pathological α-synuclein in brain , 2013, Brain : a journal of neurology.

[41]  Herbert F. Jelinek,et al.  Quantitating the subtleties of microglial morphology with fractal analysis , 2013, Front. Cell. Neurosci..

[42]  N. Cairns,et al.  Pathologic accumulation of α-synuclein and Aβ in Parkinson disease patients with dementia. , 2012, Archives of neurology.

[43]  J. Trojanowski,et al.  Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in mice , 2012, The Journal of experimental medicine.

[44]  G. Vivacqua,et al.  The role of alpha-synuclein in neurotransmission and synaptic plasticity , 2011, Journal of Chemical Neuroanatomy.

[45]  J. Kordower,et al.  Transfer of host-derived alpha synuclein to grafted dopaminergic neurons in rat , 2011, Neurobiology of Disease.

[46]  D. Dickson,et al.  Neuropathology underlying clinical variability in patients with synucleinopathies , 2011, Acta Neuropathologica.

[47]  B. Tang,et al.  Rabs, SNAREs and α-synuclein — Membrane trafficking defects in synucleinopathies , 2011, Brain Research Reviews.

[48]  R. Burke,et al.  Akt Suppresses Retrograde Degeneration of Dopaminergic Axons by Inhibition of Macroautophagy , 2011, The Journal of Neuroscience.

[49]  T. Südhof,et al.  α-Synuclein Promotes SNARE-Complex Assembly in Vivo and in Vitro , 2010, Science.

[50]  R. Burke,et al.  Clinical progression in Parkinson disease and the neurobiology of axons , 2010, Annals of neurology.

[51]  C. Richter-Landsberg,et al.  α-Synuclein Aggregation and Ser-129 Phosphorylation-dependent Cell Death in Oligodendroglial Cells* , 2009, Journal of Biological Chemistry.

[52]  R. Hauser,et al.  Lewy body–like pathology in long-term embryonic nigral transplants in Parkinson's disease , 2008, Nature Medicine.

[53]  T. Iwatsubo,et al.  Relationship of phosphorylated α-synuclein and tau accumulation to Aβ deposition in the cerebral cortex of dementia with Lewy bodies , 2008, Experimental Neurology.

[54]  R. Barbour,et al.  Phosphorylation of Ser-129 Is the Dominant Pathological Modification of α-Synuclein in Familial and Sporadic Lewy Body Disease* , 2006, Journal of Biological Chemistry.

[55]  Manuel Rodriguez,et al.  Expression of dopamine and vesicular monoamine transporters and differential vulnerability of mesostriatal dopaminergic neurons , 2004, The Journal of comparative neurology.

[56]  Erwan Bezard,et al.  Enriched Environment Confers Resistance to 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine and Cocaine: Involvement of Dopamine Transporter and Trophic Factors , 2003, The Journal of Neuroscience.

[57]  H. Braak,et al.  Staging of brain pathology related to sporadic Parkinson’s disease , 2003, Neurobiology of Aging.

[58]  Emma J. Burton,et al.  Patterns of Cerebral Atrophy in Dementia with Lewy Bodies Using Voxel-Based Morphometry , 2002, NeuroImage.

[59]  S. Hirai,et al.  Heterogeneity of Nigral and Cortical Lewy Bodies Differentiated by Amplified Triple-Labeling for Alpha-Synuclein, Ubiquitin, and Thiazin Red , 2002, Experimental Neurology.

[60]  A. Björklund,et al.  Parkinson-Like Neurodegeneration Induced by Targeted Overexpression of α-Synuclein in the Nigrostriatal System , 2002, The Journal of Neuroscience.

[61]  D. Sulzer,et al.  Substantia nigra neuromelanin: structure, synthesis, and molecular behaviour , 2001, Molecular pathology : MP.

[62]  H U Rehman,et al.  Multiple system atrophy , 2001, Postgraduate medical journal.

[63]  C. Masters,et al.  The solubility of α‐synuclein in multiple system atrophy differs from that of dementia with Lewy bodies and Parkinson's disease , 2001 .

[64]  K. Kosaka,et al.  Diffuse Lewy body disease , 2000, Neuropathology : official journal of the Japanese Society of Neuropathology.

[65]  E. Bézard,et al.  Adaptive changes in the nigrostriatal pathway in response to increased 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐induced neurodegeneration in the mouse , 2000, The European journal of neuroscience.

[66]  B. Hyman,et al.  α-Synuclein immunoreactivity in dementia with Lewy bodies: morphological staging and comparison with ubiquitin immunostaining , 2000, Acta Neuropathologica.

[67]  Philippe Hantraye,et al.  MPTP induces alpha‐synuclein aggregation in the substantia nigra of baboons , 2000, Neuroreport.

[68]  G. Halliday,et al.  The midbrain dopaminergic cell groups in the baboon papio ursinus , 1998, Brain Research Bulletin.

[69]  O. Hornykiewicz.  Biochemical aspects of Parkinson's disease , 1998, Neurology.

[70]  E. Bézard,et al.  Compensatory mechanisms in experimental and human Parkinsonism: towards a dynamic approach , 1998, Progress in Neurobiology.

[71]  R. Crowther,et al.  α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies , 1998 .

[72]  M. L. Schmidt,et al.  α-Synuclein in Lewy bodies , 1997, Nature.

[73]  T Pietsch,et al.  NeuN: a useful neuronal marker for diagnostic histopathology. , 1996, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[74]  J. Trojanowski,et al.  Lewy Bodies: Purification from Diffuse Lewy Body Disease Brains a , 1996, Annals of the New York Academy of Sciences.

[75]  K Kosaka,et al.  Diffuse type of Lewy body disease: progressive dementia with abundant cortical Lewy bodies and senile changes of varying degree--a new disease? , 1984, Clinical neuropathology.

[76]  Kenji Kosaka,et al.  Lewy bodies in cerebral cortex. Report of three cases , 1978, Acta Neuropathologica.

[77]  OUP accepted manuscript , 2021, Brain.

[78]  J. Volkmann,et al.  Parkinson disease , 2017, Nature Reviews Disease Primers.

[79]  C. Masters,et al.  The solubility of alpha-synuclein in multiple system atrophy differs from that of dementia with Lewy bodies and Parkinson's disease. , 2001, Journal of neurochemistry.

[80]  M G Spillantini,et al.  Alpha-synuclein in Lewy bodies. , 1997, Nature.

[81]  C. Marsden.  Pigmentation in the nucleus substantiae nigrae of mammals. , 1961, Journal of anatomy.